131 related articles for article (PubMed ID: 25817046)
41. Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib.
Donghi D; Dummer R; Cozzio A
Br J Dermatol; 2010 Mar; 162(3):697-9. PubMed ID: 20030640
[No Abstract] [Full Text] [Related]
42. Angiosarcoma of the scalp and face: failure of an interferon alpha treatment.
Guillot B; Raison-Peyron N; Acevedo M; Meunier L; Dandurand M; Meynadier J
Eur J Dermatol; 2000 Jun; 10(4):300-2. PubMed ID: 10846259
[TBL] [Abstract][Full Text] [Related]
43. Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options.
Semenisty V; Naroditsky I; Keidar Z; Bar-Sela G
BMC Cancer; 2015 May; 15():402. PubMed ID: 25967676
[TBL] [Abstract][Full Text] [Related]
44. Pazopanib for advanced liposarcoma.
Gilbert JA
Lancet Oncol; 2017 Oct; 18(10):e564. PubMed ID: 28844815
[No Abstract] [Full Text] [Related]
45. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Zivi A; Cerbone L; Recine F; Sternberg CN
Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
[TBL] [Abstract][Full Text] [Related]
46. The Successful Treatment of Metastatic Extraosseous Ewing Sarcoma with Pazopanib.
Mori Y; Kinoshita S; Kanamori T; Kataoka H; Joh T; Iida S; Takemoto M; Kondo M; Kuroda J; Komatsu H
Intern Med; 2018 Sep; 57(18):2753-2757. PubMed ID: 29780156
[TBL] [Abstract][Full Text] [Related]
47. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.
Kasper B; Hohenberger P
Future Oncol; 2011 Dec; 7(12):1373-83. PubMed ID: 22112314
[TBL] [Abstract][Full Text] [Related]
48. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
Penel N; Bui BN; Bay JO; Cupissol D; Ray-Coquard I; Piperno-Neumann S; Kerbrat P; Fournier C; Taieb S; Jimenez M; Isambert N; Peyrade F; Chevreau C; Bompas E; Brain EG; Blay JY
J Clin Oncol; 2008 Nov; 26(32):5269-74. PubMed ID: 18809609
[TBL] [Abstract][Full Text] [Related]
49. Treatment of scalp angiosarcoma by controlled perfusion of A. carotis externa with pegylated liposomal doxorubicin and intralesional application of pegylated interferon alfa.
Bong AB; Bonnekoh B; Schön MP; Gollnick H
J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):20-3. PubMed ID: 15692506
[TBL] [Abstract][Full Text] [Related]
50. Pazopanib: an antiangiogenic drug in perspective.
Castaneda CA; Gomez HL
Future Oncol; 2009 Nov; 5(9):1335-48. PubMed ID: 19903063
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.
Hutson TE; Davis ID; Machiels JP; De Souza PL; Rottey S; Hong BF; Epstein RJ; Baker KL; McCann L; Crofts T; Pandite L; Figlin RA
J Clin Oncol; 2010 Jan; 28(3):475-80. PubMed ID: 20008644
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness of pazopanib for local and lung metastases in Stewart-Treves syndrome.
Hayashi M; Makino T; Mori N; Mizawa M; Shimizu T
Eur J Dermatol; 2020 Feb; 30(1):68-69. PubMed ID: 32250262
[No Abstract] [Full Text] [Related]
53. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
Coens C; van der Graaf WT; Blay JY; Chawla SP; Judson I; Sanfilippo R; Manson SC; Hodge RA; Marreaud S; Prins JB; Lugowska I; Litière S; Bottomley A
Cancer; 2015 Sep; 121(17):2933-41. PubMed ID: 26033286
[TBL] [Abstract][Full Text] [Related]
54. Favorable course of pericardial angiosarcoma under paclitaxel followed by pazopanib treatment documented by cardiovascular magnetic resonance imaging.
Ong P; Greulich S; Schumm J; Backes M; Kaufmann M; Bode-Erdmann S; Ott G; Hebart H; Mahrholdt H
Circulation; 2012 Oct; 126(18):e279-81. PubMed ID: 23109517
[No Abstract] [Full Text] [Related]
55. Kinase inhibitors for refractory thyroid cancers.
Schlumberger M
Lancet Oncol; 2010 Oct; 11(10):912-3. PubMed ID: 20851683
[No Abstract] [Full Text] [Related]
56. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies.
Koontz BF; Miles EF; Rubio MA; Madden JF; Fisher SR; Scher RL; Brizel DM
Head Neck; 2008 Feb; 30(2):262-6. PubMed ID: 17685450
[TBL] [Abstract][Full Text] [Related]
57. Pazopanib in renal cell carcinoma.
Ward JE; Stadler WM
Clin Cancer Res; 2010 Dec; 16(24):5923-7. PubMed ID: 21059813
[TBL] [Abstract][Full Text] [Related]
58. Angiosarcoma of the scalp: new treatment modalities.
Wollina U; Graefe T; Füller J
J Eur Acad Dermatol Venereol; 2001 Jul; 15(4):370-1. PubMed ID: 11730063
[No Abstract] [Full Text] [Related]
59. Evaluation of pazopanib cytotoxicity to normal vascular endothelial cells in vitro: A comment on Goto et al.
Kitamura S; Yanagi T; Maeda T; Imafuku K; Hata H; Masuzawa M; Shimizu H
J Dermatol; 2019 Sep; 46(9):e341-e342. PubMed ID: 30908708
[No Abstract] [Full Text] [Related]
60. Pazopanib induced a partial response in a patient with metastatic fibrosarcomatous dermatofibrosarcoma protuberans without genetic translocations resistant to mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy and gemcitabine-docetaxel chemotherapy.
Miyagawa T; Kadono T; Kimura T; Saigusa R; Yoshizaki A; Miyagaki T; Yamada D; Masui Y; Fujita H; Sato S
J Dermatol; 2017 Mar; 44(3):e21-e22. PubMed ID: 27988943
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
